[go: up one dir, main page]

MX2013013228A - Particulas similares a virus y proceso para prepararlas. - Google Patents

Particulas similares a virus y proceso para prepararlas.

Info

Publication number
MX2013013228A
MX2013013228A MX2013013228A MX2013013228A MX2013013228A MX 2013013228 A MX2013013228 A MX 2013013228A MX 2013013228 A MX2013013228 A MX 2013013228A MX 2013013228 A MX2013013228 A MX 2013013228A MX 2013013228 A MX2013013228 A MX 2013013228A
Authority
MX
Mexico
Prior art keywords
vlps
particles
virus
preparing same
ssrna
Prior art date
Application number
MX2013013228A
Other languages
English (en)
Inventor
Denis Leclerc
Pierre Savard
Original Assignee
Folia Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Folia Biotech Inc filed Critical Folia Biotech Inc
Publication of MX2013013228A publication Critical patent/MX2013013228A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/26011Flexiviridae
    • C12N2770/26023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/26011Flexiviridae
    • C12N2770/26034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/26011Flexiviridae
    • C12N2770/26041Use of virus, viral particle or viral elements as a vector
    • C12N2770/26042Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona un proceso in vitro para preparar partículas similares a virus (VLPs) a partir de la proteína de recubrimiento de virus de mosaico de papaya recombinante y ssRNA, que permite la producción a gran escala de VLPs en alto rendimiento. También se proporcionan VLPs que comprenden ssRNA preparadas mediante el proceso in vitro. Las VLPs se pueden utilizar como adyuvantes y cuando se fusionan a un antígeno, como vacunas. También se proporciona el uso de las VLPs para la estimulación de la respuesta inmune innata.
MX2013013228A 2011-05-13 2012-05-01 Particulas similares a virus y proceso para prepararlas. MX2013013228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161485955P 2011-05-13 2011-05-13
PCT/CA2012/050279 WO2012155262A1 (en) 2011-05-13 2012-05-01 Virus-like particles and process for preparing same

Publications (1)

Publication Number Publication Date
MX2013013228A true MX2013013228A (es) 2013-12-12

Family

ID=47176093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013228A MX2013013228A (es) 2011-05-13 2012-05-01 Particulas similares a virus y proceso para prepararlas.

Country Status (11)

Country Link
US (2) US9833504B2 (es)
EP (2) EP2707480B1 (es)
JP (2) JP6213461B2 (es)
CN (2) CN103687942A (es)
AU (1) AU2012255595A1 (es)
BR (2) BR112013029143A2 (es)
CA (2) CA2835967A1 (es)
DK (1) DK2707480T3 (es)
MX (1) MX2013013228A (es)
NO (1) NO2800866T3 (es)
WO (2) WO2012155261A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2707480B1 (en) 2011-05-13 2017-08-02 Folia Biotech Inc. Virus-like particles and process for preparing same
WO2015039255A1 (en) * 2013-09-19 2015-03-26 Folia Biotech Inc. Papaya mosaic virus and virus-like particles in cancer therapy
US10098936B2 (en) 2014-04-02 2018-10-16 Case Western Reserve University Vaccination using plant virus particles linked to HER2 antigens
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
WO2016127262A1 (en) * 2015-02-12 2016-08-18 Folia Biotech Inc. Multimerized orthomyxovirus nucleoprotein and uses thereof
GB201708709D0 (en) 2017-06-01 2017-07-19 Univ York Virus like particle
MX385484B (es) * 2017-06-28 2025-03-14 Univ Mexico Nac Autonoma Vlps derivadas de virus de planta con dsrna encapsidado y metodo de sintesis.
FR3106648B1 (fr) * 2020-01-28 2022-05-27 Arkema France Structure multicouche pour le transport ou le stockage de l’hydrogene

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443969A (en) 1992-10-29 1995-08-22 Rutgers University RNA packaging system
US8101189B2 (en) * 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
BR0312474A (pt) 2002-07-05 2005-04-26 Denis Leclerc Partìcula viral adjuvante
JP2009513532A (ja) 2003-07-10 2009-04-02 サイトス バイオテクノロジー アーゲー パッケージ化ウイルス様粒子
EP2174665B1 (en) 2003-10-22 2016-11-16 ID Biomedical Corporation of Quebec Compositions and methods for activating innate and allergic immunity
CA2669345A1 (en) * 2006-11-15 2008-05-22 Folia Biotech Inc. Immunogenic affinity-conjugated antigen systems based on papaya mosaic virus and uses thereof
CA2669485C (en) 2006-11-15 2017-01-03 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
US7799281B2 (en) 2007-01-16 2010-09-21 Festo Corporation Flux concentrator for biomagnetic particle transfer device
EP2082042A4 (en) 2007-01-26 2010-08-18 Folia Biotech Inc VACCINE VACCINE FROM PAPAYA MOSAIC AGAINST SALMONELLA TYPHI AND OTHER ENTEROBACTERIAL PATHOGENS
WO2010012069A1 (en) 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
US20110105383A1 (en) 2008-09-10 2011-05-05 Magnus Hook Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
EP2707480B1 (en) 2011-05-13 2017-08-02 Folia Biotech Inc. Virus-like particles and process for preparing same

Also Published As

Publication number Publication date
WO2012155262A1 (en) 2012-11-22
EP2707480A4 (en) 2015-01-07
CN103648528A (zh) 2014-03-19
CA2835972A1 (en) 2012-11-22
CA2835967A1 (en) 2012-11-22
AU2012255595A1 (en) 2013-12-12
JP6213461B2 (ja) 2017-10-18
BR112013029143A2 (pt) 2017-07-11
EP2707027A4 (en) 2015-06-03
JP6093926B2 (ja) 2017-03-15
EP2707480B1 (en) 2017-08-02
JP2014514350A (ja) 2014-06-19
US20140154288A1 (en) 2014-06-05
JP2014519817A (ja) 2014-08-21
US9833504B2 (en) 2017-12-05
US20140255439A1 (en) 2014-09-11
CN103687942A (zh) 2014-03-26
DK2707480T3 (da) 2017-11-13
BR112013029144A2 (pt) 2017-07-11
EP2707027A1 (en) 2014-03-19
EP2707480A1 (en) 2014-03-19
NO2800866T3 (es) 2018-04-14
WO2012155261A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
MX2013013228A (es) Particulas similares a virus y proceso para prepararlas.
MX387666B (es) Composiciones y su uso en el tratamiento de citomegalovirus
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
IL236650B (en) Immunogenic combination, nucleic acids or vectors encoding it, host cells or compositions comprising them, and therapeutic uses thereof, process of producing an infectious virus and method for recombinant production of the mycobacterial antigens
JP2013216685A5 (es)
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
MX358762B (es) Procesos que utilizan vlps con cápsides resistentes a hidrolasas.
PH12017500727A1 (en) Modified virus-like particles of cmv
CA2817005A1 (en) Rabies glycoprotein virus-like particles (vlps)
MX350274B (es) Vacunas para hsv-2.
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
IN2015DN02546A (es)
IN2014DN05805A (es)
MX2014000753A (es) Procedimiento para producir antigeno viral y vacunas.
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
MX2013003470A (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
JP2014519817A5 (es)
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
DK201370530A (en) Salmonid alphavirus vaccine
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
MX2014004537A (es) Vacunas para el virus del papiloma humano y metodos para su uso.
MX2019007924A (es) Vacunas contra la influenza.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal